IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28^th to June 1^st in Vancouver, Canada.

“ISCT is a scientific gathering renowned for fostering groundbreaking ideas and innovation in cellular therapies,” said Dr. Kate Rochlin, Chief Operating Officer of IN8bio. “Our presentations represent a significant and meaningful step in our proprietary manufacturing platform towards the advancement of gamma-delta T cell therapeutics. We will demonstrate how our manufacturing process influences cellular product characteristics and our ability to generate a robust and reproducible final product. Our DeltEx gamma-delta T cell platform has enabled the development of multiple investigational candidates which are now moving into multi-center Phase 2 clinical trials and designed to target and potentially eradicate cancer cells to help improve patient outcomes.”

Details of the poster presentations are provided below, and reprints will be accessible following the sessions on the IN8bio website at https://investors.in8bio.com/news-events/events-presentations.

INB-400 DeltEx drug resistant immunotherapy (DRI) multi-center clinical trial product logistics management
Poster: #816
Session: Poster Networking Reception #1
Date/Time: May 29th, at 7pm-8:30pm PDT
Presenter: Guoling Chen, Senior Director Quality Operations, IN8bio

Healthy donor vs. Patient manufactured autologous DeltEx DRI product; TCR Repertoire sequencing
Poster: #850
Date/Time: May 29th, at 7pm-8:30pm PDT
Session: Poster Networking Reception #1
Presenter: Mariska ter Haak, Senior Director Analytical Development, IN8bio

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.